Traws Pharma Operating Income

Traws Pharma (TRAW) currently reports a operating income of $-4.1B as of May 2026. That compares with $-25M in the prior-year period — down 16209.5% year over year. Use the charts on this page to explore Traws Pharma's operating income history and peer comparisons.

Traws Pharma's operating income decreased from $-25M to $-4.1B — a 16209.5% year-over-year decrease (period ending May 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Traws Pharma reported $-4.1B in operating income as of May 2026. That compares with $-25M in the prior-year period — down 16209.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-4.1B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Traws Pharma, and consider following TRAW for alerts when major investors trade the stock.

Traws Pharma is classified in the Healthcare sector. On operating income, it currently shows $-4.1B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing TRAW with unrelated industries.